1,482
Views
24
CrossRef citations to date
0
Altmetric
Current Problems in Hypertension and Nephrology: Editorial

Current problems in hypertension and nephrology

&
Pages 2575-2578 | Published online: 27 Oct 2010

Bibliography

  • Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
  • Banach M, Kjeldsen SE, Narkiewicz K. Editorial. Controversies in hypertension treatment. Curr Vasc Pharmacol 2010;731-2
  • Gaciong Z, Symonides B. Hypertension 2010: what was new for the cardiologist? Expert Opin Pharmacother 2010; In press
  • Banach M, Barylski M, Rysz J. What should be the optimal levels of blood pressure? J-curve phenomenon. The scene after ACCORD BP publication. Evid Based Cardiol 2010;1:113-20
  • Hedner T, Oparil S, Narkiewicz K, Kjeldsen SE. The J-curve phenomenon revisited. Blood Press 2009;18:168-70
  • Desai RV, Banach M, Ahmed MI, Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol 2010;106:221-7
  • Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol 2010;733-41
  • Ramezani MA, Dastanpour M, Eshaghi SR, Determinants of awareness, treatment and control of hypertension in Isfahan, Central Iran. Arch Med Sci 2009;5:523-30
  • Ruilope LM, Segura J. ARBs and ACEIs together in the treatment of hypertension and its complications? Current practical recommendations. Expert Opin Pharmacother 2010; In press
  • Gustafsson F, Segura J, Ruilope LM. How should we manage heart failure developing in patients already treated with ACE inhibitors and beta-blockers for hypertension, diabetes or coronary disease. J Hypertension 2010;28:1595-8
  • Aronow WS. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother 2010; In press
  • Tatli E, Aktoz M, Gul C, Does carvedilol therapy reduce QT dispersion in patients with heart failure? Arch Med Sci 2008;4:404-8
  • Gasowski J, Tikhonoff V, Stolarz-Skrzypek K, Treatment of hypertension in the elderly in 2010 – a brief review. Expert Opin Pharmacother 2010; In press
  • Beckett NS, Peters R, Fletcher AE, ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98
  • Aronow WS. Why and how we should treat elderly patients with hypertension? Curr Vasc Pharmacol 2010;780-7
  • Jissho S, Shimada K, Taguchi H, Impact of electrocardiographic left ventricular hypertrophy on the occurrence of cardiovascular events in elderly hypertensive patients. The Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Circ J 2010;74:938-45
  • Kostapanos MS, Milionis HJ, Elisaf MS. Current role of statins in the treatment of essential hypertension. Expert Opin Pharmacother 2010; In press
  • Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease. Why, whom and when? Expert Opin Pharmacother 2010; In press
  • Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009;15:MS1-5
  • Stepien M, Banach M, Mikhailidis DP, Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 2009;25:1995-2005
  • Rysz J, Aronow WS, Stolarek RS, Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009;13:541-50
  • Cravedi P, Ruggenenti P, Remuzzi G. Which antihypertensive drugs are the most nephroprotective and why? Expert Opin Pharmacother 2010; In press
  • Stepien M, Banach M, Jankowski P, Rysz J. Clinical implications of non-invasive measurement of central aortic blood pressure. Curr Vasc Pharmacol 2010;747-52
  • Ruggenenti P, Cravedi P, Remuzzi G. Proteinuria: increased angiotensin-receptor blocking is not the first option. Nat Rev Nephrol 2009;5:367-8
  • Goch A, Banach M, Mikhailidis DP, Endothelial dysfunction in patients with noncomplicated and complicated hypertension. Clin Exp Hypertens 2009;31:20-30
  • Hart PD, Bakris GL. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother 2010; In press
  • Safar ME, Jankowski P. Destiffening procedure and antihypertensive therapy. Expert Opin Pharmacother 2010; In press
  • Rodriguez-Iturbe B, Correa-Rotter R. Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease. Expert Opin Pharmacother 2010; In press
  • Sethi A, Arora RR. Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci 2009;5:3-9
  • Moynihan R. Who benefits from treating prehypertension? BMJ 2010;341:c4442

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.